Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) (2019 - 2026)
Theravance Biopharma (TBPH) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, up 62.96% year-over-year from -$0.06 in Q1 2025, and down 108.7% quarter-over-quarter from $1.15 in Q4 2025.
Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.1 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.1, up 62.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 (up 286.44% YoY), and the FY2025 annual result was $2.06, up 279.13% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.1 in Q1 2026 per TBPH's latest filing, from $1.15 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.15 in Q4 2025 and troughed at -$0.55 in Q1 2022.
- A 5-year average of -$0.07 and a median of -$0.21 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) sank 154.55% in 2023, then surged 470.97% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then climbed by 19.05% to -$0.17 in 2023, then plunged by 82.35% to -$0.31 in 2024, then surged by 470.97% to $1.15 in 2025, then slumped by 108.7% to -$0.1 in 2026.
- Business Quant data shows TBPH's EPS (Weighted Average and Diluted) at -$0.1 in Q1 2026, $1.15 in Q4 2025, and $0.07 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | 1.15 |
| Sep 30, 2025 | 0.07 |
| Jun 30, 2025 | 1.08 |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | -0.31 |
| Sep 30, 2024 | -0.26 |
| Jun 30, 2024 | -0.34 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | -0.17 |
| Sep 30, 2023 | -0.17 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.35 |
| Dec 31, 2022 | -0.21 |
| Sep 30, 2022 | -0.21 |
| Jun 30, 2022 | -0.11 |
| Mar 31, 2022 | -0.55 |
| Dec 31, 2021 | -0.43 |
| Sep 30, 2021 | -0.48 |
| Jun 30, 2021 | -0.80 |